JE-2147
Also known as: AG-1776, KNI-764, KNI764
Source JE-2147 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
JE-2147 (also known as AG-1776 or KNI-764) is a peptidomimetic HIV protease inhibitor developed in the late 1990s. It incorporates a allophenylnorstatine-based core structure and demonstrates potent activity against HIV-1 and HIV-2, including some multidrug-resistant strains. It was primarily investigated as a research tool and did not advance to approved clinical use.
Mechanism of Action
Competitive inhibitor of HIV-1 and HIV-2 aspartyl protease; binds the active site of the viral protease, preventing cleavage of Gag and Gag-Pol polyprotein precursors, thereby blocking maturation of infectious viral particles.
Routes of Administration
Goals & Uses
- HIV-2 protease inhibitionAntiviralLow
- HIV-1 protease inhibitionAntiviralModerate
- Research tool for protease resistance studiesResearchModerate
- Activity against drug-resistant HIV strainsAntiviralModerate
Contraindications
- Not established for clinical useGeneralHigh
Adverse Effects
- Unknown human safety profileGeneralUnknown
Drug Interactions
- CYP3A4 substrates/inhibitorsLow
Population Constraints
- General populationGeneralAbsolute
Regulatory Status
- European UnionUnapprovedNo marketing authorization; research use only.
- United StatesUnapprovedResearch compound only; no IND or NDA filed as publicly known.
- United KingdomUnapprovedNo regulatory approval; laboratory research compound.
JE-2147 has not received regulatory approval in any jurisdiction. It remains a research/investigational compound used primarily in laboratory studies of HIV protease inhibition and resistance mechanisms.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is JE-2147?
JE-2147 (also known as AG-1776 or KNI-764) is a peptidomimetic HIV protease inhibitor developed in the late 1990s. It incorporates a allophenylnorstatine-based core structure and demonstrates potent activity against HIV-1 and HIV-2, including some multidrug-resistant strains. It was primarily investigated as a research tool and did not advance to approved clinical use.
What is JE-2147 used for?
JE-2147 is educationally associated with: HIV-2 protease inhibition, HIV-1 protease inhibition, Research tool for protease resistance studies, Activity against drug-resistant HIV strains. Educational only — not medical advice.
How is JE-2147 administered?
Recorded routes of administration: Oral.
What are the potential side effects of JE-2147?
Reported adverse effects include: Unknown human safety profile. This list is not exhaustive — consult a qualified clinician.
Who should avoid JE-2147?
Recorded contraindications: Not established for clinical use. Consult a qualified clinician before use.